Phase Ia trial of PSI 938 in patients with hepatitis C.

Trial Profile

Phase Ia trial of PSI 938 in patients with hepatitis C.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2011

At a glance

  • Drugs PSI 938 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms SAD
  • Sponsors Pharmasset
  • Most Recent Events

    • 07 Feb 2011 7- and 14-day results have been reported, according to a Pharmasset media release
    • 28 Oct 2010 Results will be presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, according to a Pharmasset media release.
    • 28 Jul 2010 Preliminary results have been announced by Pharmasset in a media release. Further results are expected in the third quarter of 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top